These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38900075)

  • 1. Postdiscontinuation Antibiotic Exposure in Hospitalized Infants at Risk for Late-onset Sepsis in the Neonatal Intensive Care Unit.
    Wade KC; Greenberg RG; Benjamin DK; Chen LL; Vo B; Ang BL; Boutzoukas A; Zimmerman K; Clark RH; Cohen-Wolkowiez M; Le J;
    Pediatr Infect Dis J; 2024 Oct; 43(10):991-996. PubMed ID: 38900075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged Post-Discontinuation Antibiotic Exposure in Very Low Birth Weight Neonates at Risk for Early-Onset Sepsis.
    Le J; Greenberg RG; Benjamin DK; Yoo Y; Zimmerman KO; Cohen-Wolkowiez M; Wade KC;
    J Pediatric Infect Dis Soc; 2021 May; 10(5):615-621. PubMed ID: 33491088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime.
    Chanderraj R; Admon AJ; He Y; Nuppnau M; Albin OR; Prescott HC; Dickson RP; Sjoding MW
    JAMA Intern Med; 2024 Jul; 184(7):769-777. PubMed ID: 38739397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External Evaluation of Population Pharmacokinetic Models of Piperacillin in Preterm and Term Patients from Neonatal Intensive Care.
    Boer-Pérez FS; Lima-Rogel V; Mejía-Elizondo AR; Medellín-Garibay SE; Rodríguez-Báez AS; Rodríguez-Pinal CJ; Milán-Segovia RDC; Romano-Moreno S
    Eur J Drug Metab Pharmacokinet; 2024 Sep; 49(5):595-607. PubMed ID: 38951408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
    Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals.
    Muller AE; De Winter BCM; Koch BCP
    J Antimicrob Chemother; 2024 May; 79(5):1093-1100. PubMed ID: 38507250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
    Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
    Landmesser KB; Clark JA; Burgess DS
    J Clin Pharmacol; 2022 Apr; 62(4):479-485. PubMed ID: 34614542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
    McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
    Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit.
    de Araujo OR; da Silva DC; Diegues AR; Arkader R; Cabral EA; Afonso MR; Louzada ME; Albertoni Ade C
    Braz J Infect Dis; 2007 Apr; 11(2):277-80. PubMed ID: 17625777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a 24-hour empiric antibiotic duration for negative early-onset sepsis evaluations to reduce early antibiotic exposure in premature infants.
    Kumar R; Setiady I; Bultmann CR; Kaufman DA; Swanson JR; Sullivan BA
    Infect Control Hosp Epidemiol; 2023 Aug; 44(8):1308-1313. PubMed ID: 36278513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study.
    Cantey JB; Wozniak PS; Pruszynski JE; Sánchez PJ
    Lancet Infect Dis; 2016 Oct; 16(10):1178-1184. PubMed ID: 27452782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis.
    Shi Q; Huang C; Chen W; Wu S; Ji J; Ying C; Wu H; Xiao Y
    Eur J Pharm Sci; 2023 Jan; 180():106334. PubMed ID: 36402309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic Use in Neonatal Intensive Care Units in China: A Multicenter Cohort Study.
    Jiang S; Zhang L; Yan W; Li S; Han J; Zhou Q; Yang Y; Lee SK; Cao Y;
    J Pediatr; 2021 Dec; 239():136-142.e4. PubMed ID: 34461063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
    Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
    JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.
    Weber N; Jackson K; McWhinney B; Ungerer J; Kennedy G; Lipman J; Roberts JA
    J Infect Chemother; 2019 Jul; 25(7):503-508. PubMed ID: 30879981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?
    Crass RL; Pai MP; Lodise TP
    J Antimicrob Chemother; 2019 Jan; 74(1):126-129. PubMed ID: 30252050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.